Biologically Active Small Molecules

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Progesterone derivative and Cyp17A1 inhibitor used to treat castration-resistant prostate cancer. It decreases androgen production and may inhibit eIF4F signaling.

Progesterone derivative and Cyp17A1 inhibitor used to treat castration-resistant prostate cancer. It decreases androgen production and may inhibit eIF4F signaling.

Progesterone derivative and Cyp17A1 inhibitor used to treat castration-resistant prostate cancer. It decreases androgen production and may inhibit eIF4F signaling.

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

Blocks CYP17A1 by potently inhibiting both the 17&alpha-hydroxylase and the 17,20 lyase activities (IC₅₀ = 18 and 17 nM, respectively) essentially eliminates plasma testosterone while producing a 3- to 4-fold increase in plasma

BH3 mimetic and Bcl-2 inhibitor. It induces apoptosis in chronic lymphocytic leukemia cells

BH3 mimetic and Bcl-2 inhibitor. It induces apoptosis in chronic lymphocytic leukemia cells